TScan Therapeutics (NASDAQ:TCRX) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

TScan Therapeutics (NASDAQ:TCRXGet Free Report) issued its quarterly earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.08, MarketWatch Earnings reports. The company had revenue of $7.21 million for the quarter, compared to analysts’ expectations of $2.94 million. TScan Therapeutics had a negative return on equity of 61.17% and a negative net margin of 423.86%.

TScan Therapeutics Stock Down 0.1 %

Shares of TScan Therapeutics stock opened at $7.14 on Friday. The company has a 50-day simple moving average of $5.99 and a two-hundred day simple moving average of $4.64. The stock has a market capitalization of $341.51 million, a PE ratio of -3.78 and a beta of 0.87. TScan Therapeutics has a 52-week low of $1.62 and a 52-week high of $7.87. The company has a debt-to-equity ratio of 0.17, a quick ratio of 6.56 and a current ratio of 6.56.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TCRX shares. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Thursday. Wedbush reissued an “outperform” rating and issued a $10.00 price target (up from $9.00) on shares of TScan Therapeutics in a research report on Wednesday. Finally, Lifesci Capital reaffirmed an “outperform” rating on shares of TScan Therapeutics in a research report on Monday, November 27th.

Read Our Latest Stock Report on TScan Therapeutics

Insider Activity

In related news, Director Timothy J. Barberich bought 28,830 shares of the stock in a transaction on Monday, December 18th. The shares were acquired at an average price of $4.89 per share, for a total transaction of $140,978.70. Following the purchase, the director now owns 66,710 shares of the company’s stock, valued at $326,211.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Thursday, December 14th. The shares were acquired at an average cost of $5.08 per share, for a total transaction of $25,400.00. Following the completion of the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at $152,400. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Timothy J. Barberich bought 28,830 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were acquired at an average price of $4.89 per share, with a total value of $140,978.70. Following the transaction, the director now directly owns 66,710 shares of the company’s stock, valued at approximately $326,211.90. The disclosure for this purchase can be found here. Corporate insiders own 8.27% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in shares of TScan Therapeutics during the second quarter worth $32,000. Renaissance Technologies LLC bought a new position in shares of TScan Therapeutics during the 1st quarter valued at about $37,000. LPL Financial LLC purchased a new position in shares of TScan Therapeutics during the second quarter valued at about $50,000. Virtu Financial LLC bought a new stake in shares of TScan Therapeutics in the fourth quarter worth about $107,000. Finally, American Century Companies Inc. purchased a new stake in shares of TScan Therapeutics in the third quarter worth about $49,000. 67.73% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

(Get Free Report)

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors.

Featured Stories

Earnings History for TScan Therapeutics (NASDAQ:TCRX)

Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.